Background: Gastric cancer is a widespread cancer and one of the leading causes of cancer death worldwide. In metastatic patients with HER2 overexpression the addition of Trastuzumab to first line chemotherapy improves tumor response and chance for survival. The optimal duration of Trastuzumab in this setting still unknown as well as the benefit of Trastuzumab continuation beyond progression in advanced gastric cancer.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.